NASDAQ:PCRX
Pacira Pharmaceuticals Stock News
$30.33
-0.130 (-0.427%)
At Close: May 31, 2024
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), AbbVie (ABBV) and Sanofi (OtherSNYNF)
02:43am, Monday, 27'th Apr 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PTC Therapeutics (PTCT), AbbVie (ABBV) and Sanofi
Stocks Showing Improved Relative Strength: Pacira Pharmaceuticals
12:00am, Friday, 24'th Apr 2020Analysts' Top Healthcare Picks: Eagle Pharmaceuticals (EGRX), Biogen (BIIB)
02:41pm, Thursday, 23'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals (EGRX) and Biogen (BIIB) with bullish
Why Pacira BioSciences, Inc.'s (NASDAQ:PCRX) CEO Pay Matters To You
12:59pm, Thursday, 23'rd Apr 2020
In 2007, Dave Stack was appointed CEO of Pacira BioSciences, Inc. (NASDAQ:PCRX). This report will, first, examine the...
Stock Traders Purchase High Volume of Call Options on Pacira Biosciences (NASDAQ:PCRX)
07:52am, Thursday, 23'rd Apr 2020
Pacira Biosciences Inc (NASDAQ:PCRX) was the target of some unusual options trading activity on Tuesday. Stock investors purchased 606 call options on the company. This represents an increase of appro
Pacira Biosciences Inc (NASDAQ:PCRX) Given Consensus Rating of "Buy" by Analysts
06:24am, Thursday, 23'rd Apr 2020
Pacira Biosciences Inc (NASDAQ:PCRX) has been assigned an average recommendation of “Buy” from the eighteen analysts that are currently covering the stock, Marketbeat reports. Seven research analy
Stifel Nicolaus Keeps a Buy Rating on Principia Biopharma (PRNB)
08:00am, Wednesday, 22'nd Apr 2020
Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Principia Biopharma (PRNB) on April 17. The company's shares closed last Tuesday at
Stifel Nicolaus Keeps a Buy Rating on Principia Biopharma (PRNB)
08:00am, Wednesday, 22'nd Apr 2020
Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Principia Biopharma (PRNB – Research Report) on April 17. The
Esperion (ESPR) Received its Third Buy in a Row
04:33pm, Monday, 20'th Apr 2020
After Needham and Merrill Lynch gave Esperion (NASDAQ: ESPR) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus.
Esperion (ESPR) Received its Third Buy in a Row
04:33pm, Monday, 20'th Apr 2020
After Needham and Merrill Lynch gave Esperion (NASDAQ: ESPR) a Buy rating last month, the company received another Buy, this
Zacks: Analysts Expect Pacira Biosciences Inc (NASDAQ:PCRX) Will Post Earnings of $0.35 Per Share
09:32am, Monday, 20'th Apr 2020
Equities research analysts expect that Pacira Biosciences Inc (NASDAQ:PCRX) will report earnings per share of $0.35 for the current quarter, according to Zacks Investment Research. Nine analysts have
Zacks: Brokerages Anticipate Pacira Biosciences Inc (NASDAQ:PCRX) Will Post Quarterly Sales of $103.10 Million
05:56am, Sunday, 19'th Apr 2020
Equities research analysts expect Pacira Biosciences Inc (NASDAQ:PCRX) to report $103.10 million in sales for the current quarter, Zacks reports. Nine analysts have issued estimates for Pacira Bioscie
Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
12:33pm, Friday, 17'th Apr 2020
After Leerink Partners and Piper Sandler gave Pacira Pharmaceuticals (NASDAQ: PCRX) a Buy rating last month, the company received another Buy, this time
Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
12:33pm, Friday, 17'th Apr 2020
After Leerink Partners and Piper Sandler gave Pacira Pharmaceuticals (NASDAQ:
PCRX
) a Buy rating last month, the company received another Buy, this time from Barclays. Analyst
Balaji Prasad
maintaine
Pacira Pharmaceuticals (PCRX) Receives a Buy from Northland Securities
11:38am, Friday, 17'th Apr 2020
Northland Securities analyst Tim Chiang maintained a Buy rating on Pacira Pharmaceuticals (PCRX) today and set a price target of $50.00. The company's
